The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A very good day today! Watch this Space!
Found the Daily Mail Article: Thanks Keep an eye on Akers Biosciences, 0.05p easier at 2.32p. Top-rated Henderson fund manager Rob Giles has personally bought a 6.5 per cent stake in the company which is involved in the development and sale of disposable diagnostic testing devices. It recently developed breathalyser technology for detecting lung cancer at early stages, as well as monitoring diabetics for their blood acid levels. It also plans to list its shares on Nasdaq.
This is one of my biggest holdings. I haven't taken any profit yet but what a surprise to my ISA today! I will look for the article but what did it say?
The Rob Giles article has been published in This Is Money website and Daily Mail newspaper. Reason why SP has increased leaps and bounds today . If Akers are accepted into NASDAQ (news imminent) expect price to climb further
2.60 paid
Looks like Rob Giles picked up Legal's stock. Not surprised they've moved up on the news, he's one of the best small cap fm's in London.
I see L&G have completely pulled out now. I don't know how the US market will respond to the NASDAQ listing. But when that happens I will expect Akers to de-list from the useless London AIM altogether. They could not justify the expense as it does not serve the purpose of raising value and funds, there are too many useless Companies listed on it (such as VIY)
Buy Akers Biosciences at 2.375p – short term target 4.5p By Hot Stock Rockets — Tuesday 8 October 2013 Interesting "players" in the small cap world are buying into AIM listed Akers Biosciences (AKR) and we suggest following suit at 2.375p with an initial target of 4.5p. Here’s why. The company is currently capitalised at just £4.72 million. As at 30th June Akers was debt free with net cash of $1.553,884 (call it £1 million). And unlike most biotechs it is actually profitable. The first half pre-tax profit (a maiden profit) was $90,235 with EBITDA $369,324. That was driven by a 235% increase in sales to $2.64 million driven by large orders for its CHUBE breathalysers. We reckon that there are more orders where those came from. So on a fundamental basis there is a decent buy case. Perhaps as importantly the company is underway with a $15 million fund raise ahead of a NASDAQ listing. Those who know this sector reckon that such a strong growth story will be valued totally differently on NASDAQ to the way it is on the bottom end of AIM and that the stock will thus enjoy a massive re-rating. Ahead of the US listing we’d buy at 2.375p with an initial 4.5p target. - See more at: http://www.shareprophets.advfn.com/views/1880/buy-akers-biosciences-at-2375p-short-term-target-45p#sthash.suxwTxuf.dpuf
Thanks for that. Pl keep us informed on US
Nasdaw listing news ..... been checking every day and this si the first time info has started to appear ... i take it they havent done it for no reason .. very interesting ....http://www.nasdaq.com/symbol/akbs/sec-filings
It was a very good update. The CEO says that this is the best shape AKers has been in for years .... and they are really miffed about the present valuation and i can see them really wanting to up the game here. So much in the pipeline. Surprised after the big volume a few weeks back we didnt have a holdings rns tho ? I think another trading update will make this go bonkers. Great products, no debt and way ahread of full yr targets already. Just waiitng now for the next leg up.
In July we were near 1p and now at 2.42. We have tested 2.60 recently and this will start moving again shortly. Many of the buys have come up as sells. Interim Results for 6 mts to 30/6/13 was very positive.
This is now one of my biggest holding! GLA
and in the process raise the $17,250,000 they are going for then that equates to a share price here of £3.8p. Then theres the updates etc, very good risk reward IMO.
if it takes off in the usa could be a huge money spinner for akers .... attached is a blog of a well know fitness guy int he usa who has been using it and promoting it ...http://www.bengreenfieldfitness.com/2013/05/low-carb-triathlon-training/ .......... there is so much going on here now that this could rerate very quickly indeed even tho already doubled in short time ...... even the CEO said that these product like the breathtest kit in france have the ability to transform profits wildly in no time at all. These have really not been in this kind of shape for a long time ... my target is 7.5p for xmas.
be the turnaround share of 2013 ... looked like it was dead and buried and going knowhere now suddendly things are looking very rosey indeeed. Looks like it now has proper commercial focused folk on board and trading statement was brilliant .... good news and natural progression could see this bag again.
Akers has recently applied to join NASDAQ. News due any day now and we think UK investors are buying up shares in anticipation. I think that the company has done a number of things in the last year which will interest investors. 1 - It has supplied disposable breathalyzers to the France after they passed a law saying that all cars foreign and French must have 2 disposables as part of a safety kit 2 - It has been lacking in the marketing dept historically but has went into partnership with BeChube who have completed a profile raising tour around Europe. We also believe they are looking to market in Africa and the US 3 -Akers are due to launch a fitness product in the lucrative US market - this will ascertain if you are burning fat or carbs when you exercise 4 - They are looking to launch a PIFA product in China. 9 year deal. Still being passed by Chinese authorities but will hopefully generate long term revenue for AKers 5 - The company has recently posted a half year profit - the first profit of any kind since 2008 albeit small 6 - The company is debt free. 7 - If another country passes a disposable breathalzyer law we believe Akers are well placed to enter that market quickly
Agree - i bought shares last December when they announced a deal to supply the French with disposable breathalzyers after the car law was passed. But they have their fingers in many pies not just that market
AUCTION!!!
I knew about the potential here. Got in last week and 30% up. Not bad but it's only the starter!
Good SP growth recently. Boosted by the first half year profits in 5 years, imminent launch of Metron ( fitness product) ,and a BeChube disposable breathalyzer marketing campaign around Europe No news about Chinese launch but hopefully not long Its been around 7 weeks since Akers applied to join NASDAQ. There should be an RNS any day now and when the Yanks get here expect the SP to rise even further!!
from look@myfraud and skums oops on the mobile typing error.
Looking good today!
1st trade this morning was mine! This time staying put as this will be one to watch in the future!
. ITS BLUE HEAVEN TODAY, . . I dont know why there are no positive signals above on the AKR Broker Ratings. . . . . . BUT dont say I never told you so